Catalog No.
DHJ48301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-Kappa
Clonality
Monoclonal
Target
PLAB, Placental bone morphogenetic protein, MIC1, NRG-1, PTGFB, NSAID-regulated gene 1 protein, GDF15, NAG-1, MIC-1, Prostate differentiation factor, NSAID-activated gene 1 protein, Growth/differentiation factor 15, Macrophage inhibitory cytokine 1, Placental TGF-beta, GDF-15, PDF
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q99988
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
PF-06946860, CAS: 2368950-15-4
Clone ID
Ponsegromab
Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues., PMID:40485364
Oncology: What You May Have Missed in 2024., PMID:40163865
New trends in supportive care of head and neck cancers., PMID:40071473
Ponsegromab for the Treatment of Cancer Cachexia. Reply., PMID:40043245
Ponsegromab for the Treatment of Cancer Cachexia., PMID:40043244
Ponsegromab for the Treatment of Cancer Cachexia., PMID:40043243
Growth differentiation factor 15 aggravates sepsis-induced cognitive and memory impairments by promoting microglial inflammatory responses and phagocytosis., PMID:39985040
Potential new treatment for cancer-related cachexia: Patients with cancer-related cachexia who were treated with ponsegromab had a significant increase in weight gain from the baseline in comparison with patients treated with a placebo., PMID:39752226
Ponsegromab for Cancer Cachexia - A New Dawn for an Old Condition?, PMID:39693547
NEJM at ESMO - Ponsegromab in Cancer Cachexia., PMID:39282941
Ponsegromab for the Treatment of Cancer Cachexia., PMID:39282907
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial., PMID:39212045
Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design., PMID:38500292
A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia., PMID:37982848
Current advancements in pharmacotherapy for cancer cachexia., PMID:36995115
For research use only. Not for human or drug use.
